Novartis Ag (NVSEF) Times Interest Earned (2009 - 2025)
Novartis Ag's (NVSEF) quarterly Times Interest Earned came in at -$16.83 in Q2 2025, down 3.15% year-on-year from -$17.38 in Q2 2024, and up 37.34% quarter-over-quarter from -$26.86 in Q4 2024.
Novartis Ag (NVSEF) Times Interest Earned (2009 - 2025) Analysis & Trends
Novartis Ag has disclosed Times Interest Earned across 15 years of filings, most recently posting -$16.83 for Q2 2025.
- Times Interest Earned for Q2 2025 came in at -$16.83, down 3.15% year-over-year; the trailing twelve-month figure through Jun 2025 was -$19.75 (down 42.44% YoY), and the FY2025 annual result was $15.42, up 6.68% from the prior year.
- Times Interest Earned came in at -$16.83 for Q2 2025 at Novartis Ag, up from -$26.86 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$1.32 in Q4 2022 to a low of -$26.86 in Q4 2024.
- The 5-year median for Times Interest Earned is -$6.6 (2021), against an average of -$9.9.
- Across the five-year window, Times Interest Earned soared 36.28% in 2022 and plunged 1795.6% in 2023, its largest moves.
- Novartis Ag's Times Interest Earned stood at -$1.87 in 2021, then rose by 29.62% to -$1.32 in 2022, then slumped by 1795.6% to -$25.0 in 2023, then declined by 7.45% to -$26.86 in 2024, then jumped by 37.34% to -$16.83 in 2025.
- The last three Times Interest Earned figures came in at -$16.83 (Q2 2025), -$26.86 (Q4 2024), and -$16.32 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | -13.73 |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 23.39 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | - |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 4.06 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 10.78 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | - |
| 10 | Novartis Ag | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -16.83 |
| Dec 31, 2024 | -26.86 |
| Jun 30, 2024 | -16.32 |
| Dec 31, 2023 | -25.00 |
| Jun 30, 2023 | -13.00 |
| Mar 31, 2023 | -1.60 |
| Dec 31, 2022 | -1.32 |
| Sep 30, 2022 | -1.83 |
| Jun 30, 2022 | -11.03 |
| Mar 31, 2022 | -1.96 |
| Dec 31, 2021 | -1.87 |
| Sep 30, 2021 | -2.18 |
| Jun 30, 2021 | -17.31 |
| Mar 31, 2021 | -1.54 |
| Dec 31, 2020 | -1.85 |
| Sep 30, 2020 | -1.89 |
| Jun 30, 2020 | -10.69 |
| Mar 31, 2020 | 0.19 |
| Jun 30, 2019 | -12.99 |
| Mar 31, 2019 | -1.21 |